美国国立卫生研究院裸盖菇素研究演讲系列：科学现状、监管和政策格局、研究差距和机遇。
National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities.
机构信息
National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD), Office of Cancer Complementary and Alternative Medicine (OCCAM), Rockville, MD, USA.
NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA.
出版信息
Neuropharmacology. 2023 Jun 1;230:109467. doi: 10.1016/j.neuropharm.2023.109467. Epub 2023 Feb 27.
The U.S. National Institutes of Health (NIH) convened a seminal first ever psychedelic drug substance-focused speaker series, from April 22 to June 10, 2021, titled the "NIH Psilocybin Research Speaker Series." This speaker series provided evidence-based scientific information to the public and the scientific community. Its aims were to assess the current state of the science, the regulatory and policy landscape, as well as to identify gaps in knowledge and understanding, ultimately serving to define future research needs. The highlights of the lectures and discussion from 26 national and international distinguished experts served as the basis for this Special Issue of Neuropharmacology. This article is part of the Special Issue on "National Institutes of Health Psilocybin Research Speaker Series".
美国国立卫生研究院（NIH）于 2021 年 4 月 22 日至 6 月 10 日召开了首次以迷幻药物物质为重点的开创性演讲者系列会议，题为“NIH 裸盖菇素研究演讲者系列”。该演讲者系列向公众和科学界提供了基于证据的科学信息。其目的是评估科学的现状、监管和政策格局，以及确定知识和理解方面的差距，最终旨在确定未来的研究需求。26 位来自国内外杰出专家的演讲和讨论的重点内容构成了本期《神经药理学》特刊的基础。本文是“NIH 裸盖菇素研究演讲者系列”特刊的一部分。
Zotero 插件